Treating Alzheimer's Disease with Monoclonal Antibodies: Current Status and Outlook for the Future

Overview

Journal Alzheimers Res Ther

Date 2013 Nov 13

PMID 24216217

Citations 26

Authors

Niels D Prins

Philip Scheltens

Affiliations

Soon will be listed here.

Abstract

In the past decade, Alzheimer's disease drug discovery has been directed at 'disease modifying drugs' that are able to counteract the progression of Alzheimer's disease by intervening in specific parts of its neuropathological process. Passive immunization with monoclonal antibodies (mAbs) may be able to clear toxic amyloid-β species either directly or through microglia or complement activation, thereby halting the amyloid cascade and preventing neurodegeneration and cognitive and functional decline. Thus far, results from two large phase 3 trial programs with bapineuzumab and solaneuzumab, respectively, have brought rather disappointing results. Possible explanations could be that these compounds were either targeting the wrong amyloid-β species, or were given too late in the disease process. Several new mAbs targeting various amyloid-β epitopes are now being tested in ongoing phase 2 and 3 clinical trials. The present review discusses the various mAbs aimed at amyloid-β, summarizes trial results and provides an outlook for the future.

Citing Articles

Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.

Reddi Sree R, Kalyan M, Anand N, Mani S, Gorantla V, Sakharkar M ACS Omega. 2025; 10(6):5148-5171.

PMID: 39989768 PMC: 11840625. DOI: 10.1021/acsomega.4c05527.

Pharmacological effects of herbal ingredients of Manasamitra vatakam in the treatment of Alzheimer's disease: A review.

Nair A, Briget Kuriakose B, Biju A, Surendran S, Sudheesh M, Lakshmi P J Ayurveda Integr Med. 2025; 16(1):101041.

PMID: 39799838 PMC: 11773069. DOI: 10.1016/j.jaim.2024.101041.

The Relevance and Implications of Monoclonal Antibody Therapies on Traumatic Brain Injury Pathologies.

Wang P, Okada-Rising S, Scultetus A, Bailey Z Biomedicines. 2025; 12(12.

PMID: 39767605 PMC: 11672875. DOI: 10.3390/biomedicines12122698.

onitoring drug fficacy through ulti-mics esearch initiative in lzheimer's isease (MEMORI-AD): A protocol for a multisite exploratory prospective cohort study on the drug response-related clinical, genetic, microbial and metabolomic signatures in....

Climacosa F, Anlacan V, Gordovez F, Reyes J, Tabios I, Manalo R BMJ Open. 2024; 14(11):e078660.

PMID: 39608999 PMC: 11603684. DOI: 10.1136/bmjopen-2023-078660.

Plasma membrane repair defect in Alzheimer's disease neurons is driven by the reduced dysferlin expression.

Bulgart H, Lopez Perez M, Tucker A, Giarrano G, Banford K, Miller O FASEB J. 2024; 38(20):e70099.

PMID: 39400395 PMC: 11486262. DOI: 10.1096/fj.202401731RR.

References

Barkhof F, Daams M, Scheltens P, Brashear H, Arrighi H, Bechten A . An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. AJNR Am J Neuroradiol. 2013; 34(8):1550-5. PMC: 8051438. DOI: 10.3174/ajnr.A3475. View

Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks D . Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2011; 69(2):198-207. DOI: 10.1001/archneurol.2011.1538. View

Bard F, Cannon C, Barbour R, Burke R, Games D, Grajeda H . Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000; 6(8):916-9. DOI: 10.1038/78682. View

Selkoe D . Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008; 192(1):106-13. PMC: 2601528. DOI: 10.1016/j.bbr.2008.02.016. View

Reichert J . Which are the antibodies to watch in 2013?. MAbs. 2012; 5(1):1-4. PMC: 3564874. DOI: 10.4161/mabs.22976. View

Tayeb H, Murray E, Price B, Tarazi F . Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?. Expert Opin Biol Ther. 2013; 13(7):1075-84. DOI: 10.1517/14712598.2013.789856. View

Moreth J, Mavoungou C, Schindowski K . Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?. Immun Ageing. 2013; 10(1):18. PMC: 3681567. DOI: 10.1186/1742-4933-10-18. View

Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F . Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis. 2011; 28(1):49-69. DOI: 10.3233/JAD-2011-110977. View

Venkataramani V, Wirths O, Budka H, Hartig W, Kovacs G, Bayer T . Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. J Alzheimers Dis. 2012; 29(2):361-71. DOI: 10.3233/JAD-2011-111379. View

10.

Ozudogru S, Lippa C . Disease modifying drugs targeting β-amyloid. Am J Alzheimers Dis Other Demen. 2012; 27(5):296-300. PMC: 10845666. DOI: 10.1177/1533317512452034. View

11.

Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H, Bussche H . Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005; 331(7512):321-7. PMC: 1183129. DOI: 10.1136/bmj.331.7512.321. View

12.

Wisniewski T, Sadowski M . Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors. BMC Neurosci. 2008; 9 Suppl 2:S5. PMC: 2604889. DOI: 10.1186/1471-2202-9-S2-S5. View

13.

Sperling R, Salloway S, Brooks D, Tampieri D, Barakos J, Fox N . Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012; 11(3):241-9. PMC: 4063417. DOI: 10.1016/S1474-4422(12)70015-7. View

14.

Benilova I, Karran E, De Strooper B . The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012; 15(3):349-57. DOI: 10.1038/nn.3028. View

15.

Roher A, Maarouf C, Daugs I, Kokjohn T, Hunter J, Sabbagh M . Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. J Alzheimers Dis. 2011; 24(2):315-25. PMC: 3172868. DOI: 10.3233/JAD-2011-101809. View

16.

Walsh D, Selkoe D . A beta oligomers - a decade of discovery. J Neurochem. 2007; 101(5):1172-84. DOI: 10.1111/j.1471-4159.2006.04426.x. View

17.

Schnabel J . Amyloid: little proteins, big clues. Nature. 2011; 475(7355):S12-4. DOI: 10.1038/475S12a. View

18.

Salloway S, Sperling R, Gilman S, Fox N, Blennow K, Raskind M . A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009; 73(24):2061-70. PMC: 2790221. DOI: 10.1212/WNL.0b013e3181c67808. View

19.

Morgan D . Immunotherapy for Alzheimer's disease. J Intern Med. 2010; 269(1):54-63. PMC: 3074967. DOI: 10.1111/j.1365-2796.2010.02315.x. View

20.

Selkoe D . Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med. 2004; 140(8):627-38. DOI: 10.7326/0003-4819-140-8-200404200-00047. View